Natural ASA 1Q presentasjon 2001 Hovedelementer 1Q 2001 Tonalin /CLA-salget Natural historiske kvartalstall Strategiske alternativer for Natural-konsernet 1
1Q 2001 Hovedelementer 1 Salgsøkning Tonalin /CLA på 72 % 1q,00 til 1q,01 Salgsøkning Tonalin /CLA på 317 % i USA/Canada 1q,00 til 1q,01 Norden/Europe på linje med siste kvartaler Bruttomargin på 59,5% 35 30 25 20 15 10 5 0 3q'00 4q'00 1q'01 2
1Q 2001 Hovedelementer 2 F&U 6,5 mill. kr. i 1Q 2001 mot 4,1 mill. kr. 1Q 2000 BASF i rute, flere studier ferdig ; positive trender Pilotanlegget i drift i juni, kostnadsrammen på 11 mill kr. holder LEF-saken avsluttet med prinsipiell enighet om forlik Nye medarbeidere, Hogne Vik og Egil Nielsen 3
1Q 2001 Hovedelementer 3 Europa-satsingen forventet effekt 2q 4q,01 OTC Pharma International Introduksjon Nederland/Belgia i mai/juni og Østerike i q3,01 Syd Afrika planlegges q4,01 I Italia vurderes ny samarbeidspartner Skandinavia/Norden Flytende Tonalin /CLA-TG i butikkhyllene i mai i Norge Lansering gjennom Norgesgruppen, Hakon og COOP (CLAREN) USA/Canada fortsetter med bred pressedekning 4
1Q 2001 Hovedelementer 4 Ny markedspakke godt mottatt hos våre kunder Midelfart investerer 6-8 mill. i A&P (Media og TV) Prosjekt igangsatt for å introdusere Tonalin /CLA i utvalgte land i Asia fra 2002/2003 5
Tonalin /CLA salg geografisk CLA-salg NO K 1.000 1Q 2001 1Q 2000 4Q 2000 Akk. 2000 Norden 6 884 11 073 5 276 34 589 Resten av Europa 2 158 1 083 245 3 190 Nord-Amerika 23 627 5 664 19 024 45 132 Resten av verden 408 1 420 1 303 5 464 Sum CLA-salg 33 077 19 240 25 848 88 375 6
Tonalin /CLA DS Sales Scandinavia/Nordic (1998) - 34 MNOK (2000) - Potential 50-60+ MNOK USA/Canada (1997) - 42 MNOK (2000) - Potential 3-400 MNOK Europe/EU (2001/2002) - 3 MNOK (2000) - Potential 350+ MNOK - UK (P4H + 2nd dist.) - BeNeLux (May/June 2001) - Østerike (q3, 2001) - Frankrike - Italia - Hellas - Spania Asia (2002/2003) - 5 MNOK (2000) - Potential 1-400 MNOK - P.R. China - Singapore - Malaysia - Indonesia - Thailand - Korea - Taiwan 7
Business Idea Shaping People VISION Develop know-how and document nutrition technologies for high value functional ingredients to the food and feed industries MISSION Develop the business potential of CLA with maximum value for Natural 8
Industry-Market Overview Pharmaceutical industry Functional Foods $ 250-300 billion Dietary Supplements $ 5-10 billion - Ethical $ 20-25 billion - OTC - VMS + Herbal Medicinal Foods $ 1-2 billion Food industry Cosmetics/Toiletry Technology for $ 45 billion Biofunctional Lipids - Skin care/colour Ingredients - Fragrancies Producers $ 15-20 billion - VMS - Specialities (Oils) $ 1.500 billion - Food - Beverages Animal Feed industry $ 15-20 billion - Ingredients 9
CLA Market Development Phase The potential of a Vitamin! Development Growth Mature Markets being defined and created. Markets being grown and developed. Markets being managed and maintained. Vit. & Min. Fiber & Proteins Probiotics Omega-3/GLA Antioxidants Prebiotics CLA Phytochemicals 10
CLA Commercial Potential Develop the business potential of CLA with maximum value for Natural Business Area NTR Potential Annual Income (MNOK) CLA in Dietary Supplements (Body Comp.) 500-1.000 CLA in Animal Feed (BASF) 300-400 CLA in Food 200-500 CLA in Cosmetics 50-100 CLA in Pharma 100-200 Success with Tonalin /CLA in DS, Feed, Food, (and Cosmetics and Pharma) is a requirement for Natural to prove capability in commercialising ingredient technologies. 11
Natural Strategic Position BIOTECH Crop/Feed Grown Feed Universities, Research Institutes & Organizations, Foundations, and Others Natural - IPR - Development BIOTECH Medicine Ingredient Supplier(s) - Commercialization Ingredient Supplier(s) Pharmaceutical Feed Manufacturer Food Manufacturer Animal Feed Functional Foods Dietary supplements and OTC PATENTS ------------REGULATORY --------------- MARKET POSITION 12
CLA from DS to Industry Test Market ; Dietary Supplements Strong CLA sales growth globally 100 s of tons Multi-National 1 consumer market segment Industrial market; CLA in Food/OTC(/Pharma&Cosmetics) Significant players evaluating opportunity Industrial capability (10.000 s tons vs. 100 s tons) Regulatory management Distribution power (global/industrial coverage needed) B2B M&S power 13
Managing external factors Legal Competing Products Regulatory Suppliers and Providers IPR (Patent & Trademark) Natural ASA - CLA Technology - CLA IPR - CLA Sales in DS - CLA License BASF Competing Companies Global Food and Pharma companies Feed DS Food Commoditisation 14
Avoid commoditization Few players Protection? Many players No protection * No willingness to invest * War on margins/costs * Patents without value 15
Requirements for Success in CLA Strong IPR and Technology protection Patent/License portfolio and Know-How Trademark(s) Developed market awareness (Business opportunity) Proof of Concept (PoC) Sales/(Potential) documented (and growing) Global industrial partner(s) invest in CLA 16
Industry players in Food & OTC Ingredient suppliers Integrators Food companies DESHEA Food comp. Pharma - OTC Roche Bayer BASF Loders Crok. Denofa Cargil Monsanto Unilever ConAgra Nestlè Danone Coca Cola Kraft Hershey National Medium/Small Already customers P&G Abbot Sanofi Nycomed Supply all Product-Market segments Products in market segments Diet, energy and snack products OTC and VMS, Moving in to Energy/Health sector 17
Natural/CLA growth opportunities ALTERNATIVE STRENGTH WEAKNESS Production Flexibility Complex alliance NTR controls Management Strategic Power mngmnt Dep. on partner(s) JV/Alliance Combined cap. Alone Control (?) Capacity Competence 18
CLA is Natural and Essential CLA is a natural essential fatty acid The human body needs it CLA is patented CLA has a wide range of application areas Natural has a unique protected position (IPR) Can substitute fat in all feed and food 19
Vedlegg 20
The TimeLine for CLA Shaping People Develop the business potential of CLA with maximum value for Natural DS Income 1979 1996 2000 2002 2004 2006 2008 2010 2012 2014 CLA discovered CLA Commercialised in DS CLA Industrialised in Feed CLA Industrialised in Food Food Royalty Income Feed Royalty Income CLA Industrialised in Cosmetics CLA Industrialised in Pharma 21
Natural kvartalstall 1. kv. 01 4. kv. 00 3. kv. 00 2. kv. 00 1. kv. 00 Driftsinntekter 34 313 26 924 22 363 25 270 20 897 Driftsresultat -2 741-9 412-5 974-1 989 175 Netto Finans 1 694 840 1 320-109 610 Ordinært resultat før skattekost -1 047-8 572-4 654-2 098 785 Periodens resultat -1 047-8 599-4 654-2 098 785 Res. pr aksje av periodens resultat -0,12-1,03-0,55-0,27 0,10 22